Repaglinide pharmacokinetics in healthy young adult and elderly subjects

Clinical Therapeutics

Volumn 21, Issue 4, 1999, Pages 702-710

  Hatorp, Vibeke ^a   Huang, Won Chin ^a   Strange, Poul ^a  

^a NOVO NORDISK INC   (United States)

Author keywords

Age; Multiple dosing; Pharmacokinetics; Repaglinide; Single dosing; Type 2 diabetes

Indexed keywords

REPAGLINIDE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUNGER; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; SWEATING; VERTIGO;

EID: 0032976307     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88321-6     Document Type: Article

References (14)

1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
2. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1995;18: 1510-1518.
3. Scheen AJ. Non-insulin-dependent diabetes mellitus in the elderly. Bailliere's Clin Endocrinol Metab. 1997;11:389-406.
4. 4. Jennings PE. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs Aging. 1997;10:323-331.
5. Campbell JW. Hypoglycemia and type II diabetes: Sulfonylureas. In: Frier B, Fisher M, eds. Hypoglycemia and Diabetes: Clinical and Physiological Aspects. London: Edward Ernold; 1993:387-392.
6. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: A consensus view. Diabetic Med. 1988;5:275-281.
7. American Diabetes Association. Physician's Guide to Non-Insulin-Dependent (Type II) Diabetes: Diagnosis and Treatment. 2nd ed. Alexandria, Va: American Diabetes Association, Inc.; 1988.
8. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47:345-351.
9. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res. 1995;27:263-266.
10. Melander A. Oral antidiabetic drugs: An overview. Diabetic Med. 1996;13(9 Suppl 6):143-147.
11. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Influence of food and age on the single-dose kinetics and effects of tolbutamide and chlorpropamide. Eur J Clin Pharmacol. 1980;17:285-293.
12. Kradjan W, Kobayashi KA, Bauer LA, et al. Glipizide pharmacokinetics: Effects of age, diabetes, and multiple dosing. J Clin Pharmacol. 1989;29:1121-1127.
13. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycemic drugs. Clin Pharmacokinet. 1987;12:379-401.
14. ®. 53rd ed. Montvale, NJ: Medical Economics Company; 1999:2488-2490.